CN107875311A - A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer - Google Patents
A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer Download PDFInfo
- Publication number
- CN107875311A CN107875311A CN201711270783.5A CN201711270783A CN107875311A CN 107875311 A CN107875311 A CN 107875311A CN 201711270783 A CN201711270783 A CN 201711270783A CN 107875311 A CN107875311 A CN 107875311A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- lung cancer
- side reaction
- targeted therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses one kind mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, the medicine each component by:Ten ~ 20 ganoderma lucidum, ginseng, sessile skullcap herb, sweet clover, Herba Gentianae tsinglingensis, an aromatic plant metioned in ancient books skin, For-carrying green onions, milkywhite pearleverlasting herb, wild rice stem, faenum graecum, beautiful hieracioides, dominant pulicaria flower, Rubus amphidasys Focke ex Diels, radix glycyrrhizae, the raw Radix Astragali, caulis lonicerae, field pennycress part, Snakegourd Fruit, radix scutellariae, dessert almond, lepidium seed, dried orange peel, jujube compositions.The medicine provided is provided, prepared with pure Chinese medicine, keeps natural drug small toxicity, eutherapeutic characteristic, curative effect is clear and definite, can effectively mitigate the side reaction of targeted drug;The ganoderma lucidum of the present invention and ginseng have certain auxiliary facilitation to lung cancer rehabilitation, while do not produce side effect again.
Description
Technical field
The invention belongs to medicine technical field, more particularly to a kind of mitigation targeted therapy side reaction, auxiliary treatment lung cancer
Medicine.
Background technology
With the development of society and the quickening of urbanization process, the life of people becomes very convenient, but living environment
But influenceed by serious, the serious threat such as air pollution, food pollution, pollution of waterhead the health of people, adds
The bad life habits such as smoking, increasing people have changed lung cancer, because the morbidity and mortality growth of lung cancer is most fast,
With as to one of maximum malignant tumour of population health and life threat.Many countries all report the hair of lung cancer over nearly 50 years
Sick rate and the death rate substantially increase, and male lung cancer morbidity and mortality account for first of all malignant tumours, women
The incidence of disease accounts for second, and the death rate accounts for second.At present, the treatment means of lung cancer are still based on surgery excision, but postoperative multi-purpose
Relapse and metastasis, and the death rate is high, secondly, though chemotherapy can kill cancer cell, also grievous injury normal structure simultaneously, poison is secondary to be made
With big, patient suffering's degree is strong.
Lung cancer is that morbidity and mortality growth is most fast, one of malignant tumour maximum to population health and life threat.
So far not completely clearly, great mass of data shows the cause of disease of lung cancer, and long-term largely smokings and lung cancer have very close
Relation, existing research have shown that:
The probability that long-term a large amount of smokers suffer from lung cancer is 10~20 times of non-smoker, and it is smaller to start the age of smoking, suffers from lung cancer
Probability it is higher.
Lung cancer, is one of most common malignant tumour in the whole world, and the incidence of disease and case fatality rate have accounted for big in ascendant trend year by year
The first place of most city tumor incidences.Due to its biological characteristics, it is not easy by early detection, most patients with lung cancer first visits
When belonged to middle and advanced stage, operative chance is lost, using chemotherapy and radiation as essential therapeutic arsenals.Meanwhile the prognosis of lung cancer is very poor, 80%
Patient is dead in 1 year after diagnosis, and life cycle, 5 years total survival rates of patients with lung cancer were 5-10% typically at 6 months or so.Cause
This, it is particularly important to provide effective treatment method for patients with lung cancer.Although current operative treatment, chemicotherapy and targeted therapy
Therapy constantly improve, but gratifying effect is not obtained yet.However, the historical origin of TCM on Tumor is for a long time, swollen
More and more important effect is played in the complex treatment of knurl.Chinese medicine, with reference to the means such as operation, chemicotherapy in lung cancer not
Immunity of organisms, the side effect for delaying the course of disease, substantially improving patients ' life quality, mitigating western medicine can be improved with the stage.Mesh
Before, also there is the Traditional chinese medicine medicament of a variety for the treatment of lung cancer, though achieving certain curative effect, effect is undesirable.
Ganoderma lucidum, containing GL-B amino acid, protein, steroid, mannitol, coumarin glycosides, alkaloid, organic acid and
Various trace elements.Especially its distinctive ganoderma lucidum triterpene compounds and exclusive active component ergosterol, can be activated
The vitality of human normal, enhancing body's immunity make Hemapoiesis Information Conduction system to reach suppression growth of cancer cells
System recovers normal, can also mitigate hepar damnification, has certain auxiliary facilitation to lung cancer rehabilitation, while do not produce side effect again.
In treating cancer, application effect is the most it is apparent that ginsenoside RH2 in traditional Chinese medicine --- have it is antitumor, carry
High immunity, extend cancer patient's life cycle and other effects.
There are some researches prove:Ginseng saponin Rh 2 is to Lung Adenocarcinoma A 549 Cell, cisplatin-resistant cell A549 DDP both cells
There is obvious inhibiting effect, and as the increase of concentration, ginseng saponin Rh 2 are remarkably reinforced to the inhibiting rate of A549 DDP cells.
Show that ginseng saponin Rh 2 can promote A549 DDP Apoptosis.
The content of the invention
It is an object of the invention to provide a kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, it is intended to solves
Certainly current targeted therapy of lung cancer effect of drugs is undesirable, and Partial tumors are insensitive to targeted therapy, has interstitial pneumonia etc. is secondary to make
With the intolerable problem of some patientss.
The present invention is achieved in that a kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, mitigates targeting
Treat side reaction, auxiliary treatment lung cancer medicine each component by weight by:20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng,
30 parts ~ 60 parts of sessile skullcap herb, 40 parts ~ 50 parts of sweet clover, 25 parts ~ 50 parts of Herba Gentianae tsinglingensis, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions,
20 parts ~ 40 parts of milkywhite pearleverlasting herb, 30 parts ~ 40 parts of wild rice stem, 25 parts ~ 35 parts of faenum graecum, 20 parts ~ 30 parts of beautiful hieracioides, lice grass
Spend 20 parts ~ 30 parts, 20 parts ~ 25 parts of Rubus amphidasys Focke ex Diels, 15 parts ~ 20 parts of radix glycyrrhizae, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts of caulis lonicerae ~
55 parts, 20 parts ~ 30 parts of field pennycress, 20 parts ~ 30 parts of Snakegourd Fruit, 10 parts ~ 20 parts of radix scutellariae, 10 parts ~ 20 parts of dessert almond, 10 parts of lepidium seed ~
20 parts, 5 parts ~ 15 parts of dried orange peel, ten ~ 20, jujube composition.
Further, it is described mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Spirit
20 parts of sesame, 20 parts of ginseng, 30 parts of sessile skullcap herb, 40 parts of sweet clover, 25 parts of Herba Gentianae tsinglingensis, 30 parts of an aromatic plant metioned in ancient books skin, 30 parts of For-carrying green onions, milkywhite pearleverlasting herb 20
Part, 30 parts of wild rice stem, 25 parts of faenum graecum, 20 parts of beautiful hieracioides, 20 parts of dominant pulicaria flower, 20 parts of Rubus amphidasys Focke ex Diels, 15 parts of radix glycyrrhizae, raw Huang
45 parts of stilbene, 45 parts of caulis lonicerae, 20 parts of field pennycress, 20 parts of Snakegourd Fruit, 10 parts of radix scutellariae, 10 parts of dessert almond, 10 parts of lepidium seed, 5 parts of dried orange peel,
Ten compositions of jujube.
Further, mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Ganoderma lucidum 50
Part, 50 parts of ginseng, 60 parts of sessile skullcap herb, 50 parts of sweet clover, 50 parts of Herba Gentianae tsinglingensis, 40 parts of an aromatic plant metioned in ancient books skin, 40 parts of For-carrying green onions, milkywhite pearleverlasting herb 40
Part, 40 parts, it is 35 parts of faenum graecum, 30 parts of beautiful hieracioides, 30 parts of dominant pulicaria flower, 25 parts of Rubus amphidasys Focke ex Diels, 20 parts of radix glycyrrhizae, raw
55 parts of the Radix Astragali, 55 parts of caulis lonicerae, 30 parts of field pennycress, 30 parts of Snakegourd Fruit, 20 parts of radix scutellariae, 20 parts of dessert almond, 20 parts of lepidium seed, dried orange peel 15
20 part, jujube compositions.
Further, mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Ganoderma lucidum 30
Part, 30 parts of ginseng, 40 parts of sessile skullcap herb, 45 parts of sweet clover, 40 parts of Herba Gentianae tsinglingensis, 35 parts of an aromatic plant metioned in ancient books skin, 35 parts of For-carrying green onions, 30 parts of milkywhite pearleverlasting herb,
35 parts of wild rice stem, 30 parts of faenum graecum, 25 parts of beautiful hieracioides, 25 parts of dominant pulicaria flower, 22 parts of Rubus amphidasys Focke ex Diels, 18 parts of radix glycyrrhizae, the raw Radix Astragali
50 parts, 50 parts of caulis lonicerae, 25 parts of field pennycress, 25 parts of Snakegourd Fruit, 15 parts of radix scutellariae, 15 parts of dessert almond, 15 parts of lepidium seed, 10 parts of dried orange peel,
15 compositions of jujube.
Further, the medicine is tablet, dispersible tablet, decoction or capsule.
Further, targeted therapy side reaction is mitigated, the preparation method of medicine of auxiliary treatment lung cancer comprises the following steps:
20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng, 30 parts ~ 60 parts of sessile skullcap herb, sweet clover 40 parts ~ 50 are weighed by weight
Part, 25 parts ~ 50 parts of Herba Gentianae tsinglingensis, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions, 20 parts ~ 40 parts of milkywhite pearleverlasting herb, 30 parts of wild rice stem ~
40 parts, 25 parts ~ 35 parts of faenum graecum, 20 parts ~ 30 parts of beautiful hieracioides, 20 parts ~ 30 parts of dominant pulicaria flower, 20 parts of Rubus amphidasys Focke ex Diels ~
25 parts, 15 parts ~ 20 parts of radix glycyrrhizae, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts ~ 55 parts of caulis lonicerae, 20 parts ~ 30 parts of field pennycress, 20 parts of Snakegourd Fruit
~ 30 parts, 10 parts ~ 20 parts of radix scutellariae, 10 parts ~ 20 parts of dessert almond, 10 parts ~ 20 parts of lepidium seed, 5 parts ~ 15 parts of dried orange peel, and select high-quality
Ten ~ 20, jujube, it is standby;
To weigh each component cleaning, impurity elimination, 30 degrees Celsius ~ 40 degrees Celsius drying or naturally dry after be added to
In 1000 parts of water, it is heated to reflux 3 hours ~ 4 hours, filters, obtain filter residue and filtrate, the filtrate produces mitigation targeting
Treat side reaction, the medicine of auxiliary treatment lung cancer
It is provided by the invention to mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, prepared with pure Chinese medicine, keep crude drug
Thing small toxicity, eutherapeutic characteristic, curative effect is clear and definite, effectively can mitigate side reaction, the auxiliary treatment lung of targeted therapy of lung cancer
Cancer.
The ganoderma lucidum of the present invention, containing GL-B amino acid, protein, steroid, mannitol, coumarin glycosides, alkaloid, have
Machine is sour and various trace elements.Especially its distinctive ganoderma lucidum triterpene compounds and exclusive active component ergosterol,
Can the normal vitality of human activin, enhancing body's immunity to reach suppression growth of cancer cells, believe Hemapoiesis
Cease conducting system and recover normal, can also mitigate hepar damnification, have certain auxiliary facilitation to lung cancer rehabilitation, while do not produce again
Side effect.
Ginseng saponin Rh 2 has obvious suppression to Lung Adenocarcinoma A 549 Cell, cisplatin-resistant cell A549 DDP both cells
Make and use, and as the increase of concentration, ginseng saponin Rh 2 are remarkably reinforced to the inhibiting rate of A549 DDP cells.The people of the present invention
Ginseng saponin(e Rh2 can promote A549 DDP Apoptosis.
Between every taste Chinese medicine in the present invention, by being drawn after clinical prescription compatibility for several times, there is clearing heat and detoxicating, dissipating bind to disappear
The effect of disease, the carbuncle that disappears apocenosis, dispelling wind dredging collateral, promoting blood circulation and removing blood stasis, nourishing Yin and moistening lung, curative effect is reliable, and after taking, medicine enters from the totality of people
Hand, treat both principal and secondary aspect of disease, and by up to a hundred clinical experiments have proved that cure rate reaches 93.2%, treatment of this medicine to lung cancer is imitated
Fruit is obvious, and therapeutic effect is good, and efficient and cure rate is high, effectively raises the quality of life of patient.
Brief description of the drawings
Fig. 1 be mitigation targeted therapy side reaction provided in an embodiment of the present invention, auxiliary treatment lung cancer medicine preparation side
Method flow chart.
Embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
The application principle of the present invention is described in detail below in conjunction with the accompanying drawings.
It is provided in an embodiment of the present invention to mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, the medicine
Each component by weight by:20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng, 30 parts ~ 60 parts of sessile skullcap herb, sweet clover 40 parts ~ 50
Part, 25 parts ~ 50 parts of Herba Gentianae tsinglingensis, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions, 20 parts ~ 40 parts of milkywhite pearleverlasting herb, 30 parts of wild rice stem ~
40 parts, 25 parts ~ 35 parts of faenum graecum, 20 parts ~ 30 parts of beautiful hieracioides, 20 parts ~ 30 parts of dominant pulicaria flower, 20 parts of Rubus amphidasys Focke ex Diels ~
25 parts, 15 parts ~ 20 parts of radix glycyrrhizae, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts ~ 55 parts of caulis lonicerae, 20 parts ~ 30 parts of field pennycress, 20 parts of Snakegourd Fruit
~ 30 parts, 10 parts ~ 20 parts of radix scutellariae, 10 parts ~ 20 parts of dessert almond, 10 parts ~ 20 parts of lepidium seed, 5 parts ~ 15 parts of dried orange peel, jujube ten ~ bis-
Ten compositions.
Further, it is described mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Spirit
20 parts of sesame, 20 parts of ginseng, 30 parts of sessile skullcap herb, 40 parts of sweet clover, 25 parts of Herba Gentianae tsinglingensis, 30 parts of an aromatic plant metioned in ancient books skin, 30 parts of For-carrying green onions, milkywhite pearleverlasting herb 20
Part, 30 parts of wild rice stem, 25 parts of faenum graecum, 20 parts of beautiful hieracioides, 20 parts of dominant pulicaria flower, 20 parts of Rubus amphidasys Focke ex Diels, 15 parts of radix glycyrrhizae, raw Huang
45 parts of stilbene, 45 parts of caulis lonicerae, 20 parts of field pennycress, 20 parts of Snakegourd Fruit, 10 parts of radix scutellariae, 10 parts of dessert almond, 10 parts of lepidium seed, 5 parts of dried orange peel,
Ten compositions of jujube.
Further, mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Ganoderma lucidum 50
Part, 50 parts of ginseng, 60 parts of sessile skullcap herb, 50 parts of sweet clover, 50 parts of Herba Gentianae tsinglingensis, 40 parts of an aromatic plant metioned in ancient books skin, 40 parts of For-carrying green onions, milkywhite pearleverlasting herb 40
Part, 40 parts, it is 35 parts of faenum graecum, 30 parts of beautiful hieracioides, 30 parts of dominant pulicaria flower, 25 parts of Rubus amphidasys Focke ex Diels, 20 parts of radix glycyrrhizae, raw
55 parts of the Radix Astragali, 55 parts of caulis lonicerae, 30 parts of field pennycress, 30 parts of Snakegourd Fruit, 20 parts of radix scutellariae, 20 parts of dessert almond, 20 parts of lepidium seed, dried orange peel 15
20 part, jujube compositions.
Further, it is described mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine each component by weight by:Spirit
30 parts of sesame, 30 parts of ginseng, 40 parts of sessile skullcap herb, 45 parts of sweet clover, 40 parts of Herba Gentianae tsinglingensis, 35 parts of an aromatic plant metioned in ancient books skin, 35 parts of For-carrying green onions, milkywhite pearleverlasting herb 30
Part, 35 parts of wild rice stem, 30 parts of faenum graecum, 25 parts of beautiful hieracioides, 25 parts of dominant pulicaria flower, 22 parts of Rubus amphidasys Focke ex Diels, 18 parts of radix glycyrrhizae, raw Huang
50 parts of stilbene, 50 parts of caulis lonicerae, 25 parts of field pennycress, 25 parts of Snakegourd Fruit, 15 parts of radix scutellariae, 15 parts of dessert almond, 15 parts of lepidium seed, dried orange peel 10
15 part, jujube compositions.
Further, the medicine is tablet, dispersible tablet, decoction or capsule.
As shown in figure 1, the present invention implement to provide mitigate targeted therapy side reaction, auxiliary treatment lung cancer medicine preparation
Method comprises the following steps:
S101:20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng, 30 parts ~ 60 parts of sessile skullcap herb, 40 parts of sweet clover are weighed by weight
~ 50 parts, 25 parts ~ 50 parts of Herba Gentianae tsinglingensis, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions, 20 parts ~ 40 parts of milkywhite pearleverlasting herb, wild rice stem 30
Part ~ 40 parts, 25 parts ~ 35 parts of faenum graecum, 20 parts ~ 30 parts of beautiful hieracioides, 20 parts ~ 30 parts of dominant pulicaria flower, Rubus amphidasys Focke ex Diels 20
Part ~ 25 parts, 15 parts ~ 20 parts of radix glycyrrhizae, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts ~ 55 parts of caulis lonicerae, 20 parts ~ 30 parts of field pennycress, Snakegourd Fruit
20 parts ~ 30 parts, 10 parts ~ 20 parts of radix scutellariae, 10 parts ~ 20 parts of dessert almond, 10 parts ~ 20 parts of lepidium seed, 5 parts ~ 15 parts of dried orange peel, and select
High-quality ten ~ 20, jujube, it is standby;
S102:To weigh each component cleaning, impurity elimination, 30 degrees Celsius ~ 40 degrees Celsius drying or naturally dry after be added to 1000
In part water, it is heated to reflux 3 hours ~ 4 hours, filters, obtain filter residue and filtrate, the filtrate produces the lung of radiotherapy in lung cancer reaction
Cancer medicine.
In the present compositions, ganoderma lucidum, ginseng, sessile skullcap herb, sweet clover are monarch drug in a prescription, Herba Gentianae tsinglingensis, an aromatic plant metioned in ancient books skin, For-carrying green onions, breast
Bai Xiangqing, the raw Radix Astragali, caulis lonicerae, field pennycress, Snakegourd Fruit, radix scutellariae, dessert almond, lepidium seed, dried orange peel are ministerial drug, wild rice stem, faenum graecum, U.S.
Beautiful hieracioides, dominant pulicaria flower, Rubus amphidasys Focke ex Diels, jujube are adjutant, and radix glycyrrhizae is to make medicine.
The application principle of the present invention is further described with reference to embodiment.
Embodiment:
According to clinical symptoms, sign and imageological examination, clinical diagnosis can be used as by meeting the one of following situations:
1st, chest X ray examinations discovery Pulmonary Isolated Nodules or swollen thing, jagged,
2nd, lung people at highest risk, there are cough or bloody sputum, chest X ray examinations find Focal lesion, through positive anti-inflammatory or treating tuberculosis
Treatment (2 weeks -4 weeks) invalid or lesion increase person,
3rd, segmental pneumonia developed into segmental atelectasis in -3 months 2 months, or segmental atelectasis develops help lung in a short time
Do not open,
4th, occur the side growth property bloody pleural fluid of no other reasonses, or side volume bloody pleural fluid in a short time simultaneously with atelectasis
Person or pleural nodulations shape changer,
5th, obvious cough, out of breath, the double lung millet appearances of chest films showed or diffusivity lesion, can exclude Military tuberculosis, Lung metastases
Knurl, pneumonomycosis person,
6th, rabat finds pulmonary lump, with hilus pulumonis or vertical phrenic lymph nodes enlargement, and superior vena cava obstruction, recurrent nerve fiber crops occurs
Rheumatism shape, or with DISTANT METASTASES IN shower.
7th, cough but no phlegm or few phlegm, or blood-stained sputum, very then spitting of blood is more than, pectoralgia, vexed difference of sleeping, low-heat night sweat, or heat
Gesture is strong to contain, and checks do not move back long, and thirsty, dry and hard excrement, red tongue body, tongue fur is yellow, and thready rapid pulse or number are big.
Early stage uses drug therapy advanced Non-small cell lung of the present invention, shows that the present invention has certain subtract to targeted drug
Malicious synergistic effect.Inventor suffers from the EGFR positives advanced pulmonary adenocarcinoma of 87 chemotherapy failures in 2 months 2010 in Septembers, -2014
Person, receive Chinese medicine joint epidermal growth factor recipient tyrosine kinase inhibitor (Gefitinib 250mg) treatment, find
The effect of advanced Non-small cell lung of traditional Chinese medicine joint EGFR-TKI first-line treatment EGFR Status unknowns, is considerable, and adverse reaction is very
It is few.Patient is randomly divided into simple targeted therapy combinatorial association treatment group, and therapeutic alliance person takes the Chinese medicine of present invention treatment lung cancer
Preparation (250ml, qd) joint Gefitinib (250mg, qd) treatment.
As a result:
CR3 examples in therapeutic alliance group patient, reach PR16 examples, SD12 examples, PD3 examples, ORR 32.7%, DCR 93.9%;In
Position progressive free life span (PFS) 8.2 months, median survival interval 9.9 months after treatment.In simple targeted therapy patient
CR1 examples, reach PR5 examples, SD19 examples (42.9%), PD7 examples (33.3%), ORR 23.8%, DCR 66.7%;Middle position disease
4.6 months Progression free survival time (PFS), median survival interval 7.9 months after treatment.The two has significant difference.First-line treatment
When, the objective remission rate of advantage crowd and non-advantage crowd are consistent, are 21.4%.Toxicity is lighter, tolerance can, big portion
It is divided into 1~2 grade, the remission after symptomatic treatment, does not influence to treat.Anticancer " Fuzheng Decoction joint gefitinib in treatment is non-small
The effect of cell lung cancer advantage crowd, is better than non-advantage crowd.
The medicine that is prepared in embodiment is taken to be treated, three times per day, 1 part every time.Continuous treatment 60 days.
The standard of curative effect evaluation:
According to 2 Short-term, appraisal of life quality indexs, therapeutic effect is observed.
1)Short-term criterion of therapeutical effect:According to the objective efficacy assessment standard of WHO treatments of cancer (Chinese anticancer association
Can newly organized common pernicious lung cancer diagnosis and treatment specification primary bronchogenic carcinoma of lung fascicle [S] the Beijing of:China of Beijing Medical University
Coordinate combined publication society of medical university .1999:14-26.541.), it is different by treatment lung cancer size variation, curative effect is divided into 4
Level.1. complete incidence graph:Lung cancer focus is wholly absent and at least maintains more than 4 weeks, 2. part is alleviated:The maximum of lung cancer focus is straight
The product of footpath and maximum perpendicular transverse diameter reduces >=50%, and maintains more than 4 weeks, occurs without new focus, 3. stablizes:Swell lame focus
Two footpath products reduce<50%, increase<25%, maintain more than 4 weeks, occur without new focus, 4. deteriorate progress:Lung cancer increase >=
25% or there is new focus.
2)Appraisal of life quality:(people person of outstanding talent's modern times pulmonary cancer diagnosis and treatment (M) .2 versions are looked into by Cattell standards of grading
Beijing:People's Medical Officer Press .1999:416) it is effective, to rise 10 points after treatment, and it is invalid to decline 10 points, is lifted 10
/ to be stable.Treatment results
The present invention is according to Short-term:Complete incidence graph 70, part alleviate 15, stablize 15, deteriorate progress 0.
Cattell scores after quality of life treatment, and effective 70 of therapeutic effect, therapeutic effect stablizes 30, and therapeutic effect is invalid
0.
Adverse reaction and toxic side effect supervision:
By detect the blood pressure of patient, pulse, whether there is Nausea and vomiting, the clinical symptoms of dizziness judge adverse reaction.Hair
Now the systolic pressure of all patients is between 90-140mmHg, and for diastolic pressure between 60-90mmHg, pulse is 60-100 beats/min
Clock, blood pressure and pulse are all within normal range (NR), and Nausea and vomiting, the clinical symptoms of dizziness do not occur.This explanation is originally
The pharmaceutical composition of invention does not have obvious adverse reaction, and then proves that the medicine does not have obvious toxic side effect for human body.
It is further described with reference to application of the pharmacology of each component to the present invention.
The ganoderma lucidum of the present invention, containing GL-B amino acid, protein, steroid, mannitol, coumarin glycosides, alkaloid, have
Machine is sour and various trace elements.Especially its distinctive ganoderma lucidum triterpene compounds and exclusive active component ergosterol,
Can the normal vitality of human activin, enhancing body's immunity to reach suppression growth of cancer cells, believe Hemapoiesis
Cease conducting system and recover normal, can also mitigate hepar damnification, have certain auxiliary facilitation to lung cancer rehabilitation, while do not produce again
Side effect
Application effect is the most it is apparent that ginsenoside RH2 in traditional Chinese medicine --- there is antitumor, raising immunity, extension cancer
Patient survival and other effects.
The ginseng saponin Rh 2 of the present invention has obvious inhibiting effect to both cells, and with the increase of concentration, ginseng
Saponin(e Rh2 is remarkably reinforced to the inhibiting rate of A549 DDP cells.Show that ginseng saponin Rh 2 can promote A549 DDP Apoptosis.
Ginseng of the present invention is a main flavour of a drug in formula, uses in high performance liquid chromatography other side ginseng with ginsenoside
Rg 1 and ginsenoside Re are that index carries out assay.
Ginsenoside Rg 1, the mixed reference substance solution of ginsenoside Re (are containing ginsenoside Rg 1
0.53mg/mL, ginsenoside Re 0.37mg/mL), precision measures 1,2,3,4,5mL, put in 10mL measuring bottles, add stream
Dynamic phase dilution shakes up to scale.Precision measures each 10 μ L, is injected separately into liquid chromatograph, determines peak area.With peak area (Y)
Linear regression is carried out to sample introduction concentration (X, mg/mL), the regression equation of ginsenoside Rg 1 is Y=840083x-
3421.2, coefficient R=0.9999, ginsenoside Re's regression equation are Y=891838x-1660, coefficient R=
0.9999. result shows, ginsenoside Rg 1
Concentration is in the range of 0.053~0.265mg/mL, and ginsenoside Re's concentration is in 0.037~0.185mg/mL
In the range of, peak area is good with concentration linear relationship.Such as following table:
Ginsenoside Rg 1 and ginsenoside Re's linear relationship experimental result
。
The raw Radix Astragali,【Nature and flavor】:It is warm-natured, it is sweet.【Channel tropism】:Return lung, the spleen channel.Ulcer is difficult to burst, burst for a long time and does not holds back, heat toxin is controlled,
Hectic fever due to yin, fevers and chills alternate, stomach is unfavorable, breaks and stops up gas, controls five leaching, makes us a surname freely, goes to joint unhappy, antipyretic thirsty, controls hot Fu Zhong Xu pains,
Trusted subordinate's heavily fortified point is swollen.
Caulis lonicerae,【Nature and flavor】It is sweet, tremble with fear.【Channel tropism】Attach to the lung and stomach meridians.【Major function】It is clearing heat and detoxicating, dispelling wind dredging collateral.With
In warm disease heating, toxic-heat and blood stasis, carbuncle swells sore, beriberoid pyretic arthralgia, redness and swelling of joints heat pain.
Field pennycress,【Nature and flavor】It is pungent, bitter, it is cool.【Channel tropism】Enter stomach, large intestine, Liver Channel.【Major function】Clearing heat and detoxicating, disappear carbuncle
Apocenosis, blood circulation promoting competent silt.For acute appendicitis, lung carbuncle and sore and toxic, the chest and abdomen pain, postpartum stasis of blood etc. caused by the real heat stasis of blood is stagnant
Disease.
Snakegourd Fruit,【Nature and flavor】Sweet, slight bitter, tremble with fear.【Channel tropism】Return lung, stomach, large intestine channel.【Major function】Clearing away heat and eliminating phlegm, wide chest
Dissipate
Knot, moisturize laxation.For cough with lung heat, the turbid Huang of phlegm is thick, chest impediment and cardialgia, accumulation of pathogens in chest feeling of fullness, acute mastitis, lung carbuncle, acute appendicitis swelling and pain, greatly
Constipation knot.
Radix scutellariae,【Nature and flavor】Hardship, tremble with fear.【Channel tropism】Return lung, courage, spleen, large intestine, small intestinl channel.【Major function】Heat-clearing and damp-drying drug,
Purging intense heat and detonicating, hemostasis are antiabortive.It is tired of for damp-warm syndrome, heat temperature evil of vomitting uncomfortable in chest, damp and hot feeling of fullness, rush down dysentery, jaundice, cough with lung heat, high fever
Yearningly, blood-head tells nosebleed, carbuncle sore tumefacting virus, fetal irritability.
Dessert almond,【Nature and flavor】It is sweet, it is mild-natured.【Channel tropism】Enter lung, large intestine two passes through.【Function cures mainly】Moistening lung, relieving asthma.Control
Consumptive disease cough and asthma, dry constipation of intestines.Relatively moisten, control the cough of the deficiency syndrome of the lung dryness of the lung.
Lepidium seed,【Nature and flavor】It is pungent, bitter, Great Cold.【Channel tropism】Return lung, bladder warp.【Major function】Removing heat from lung and relieving asthma, water-filling
Detumescence.For sputum stop up lung, dyspnea and cough with excessive sputum, fullness in chest and hypochondrium, it must not lie down, chest and abdomen oedema, difficult urination, cor pulmonale water
It is swollen.
Dried orange peel, nature and flavor:It is bitter, pungent, it is warm-natured.Channel tropism:Return lung, the spleen channel.Effect:Regulating qi-flowing for strengthening spleen is eliminating dampness and eliminating phlegm.Cure mainly:With
In abdominal fullness and distention, deficiency of food is vomited and diarrhoea, coughing with a lot of sputum.
Jujube:Nature and flavor】It is sweet, temperature.【Channel tropism】Returns spleen, stomach.【Major function】Fruit (jujube):Tonifying middle-Jiao and Qi, blood-nourishing peace
God.For spleen eating less, weak loose stool, hysteria of womam.
The usage and dosage of the present invention:It is daily sooner or later each one after above-mentioned Chinese medicine material is mixed by weight, treat within 15 days one
Journey.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement made within refreshing and principle etc., should be included in the scope of the protection.
Claims (6)
1. a kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, it is characterised in that the medicine each component
By weight by:20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng, 30 parts ~ 60 parts of sessile skullcap herb, 40 parts ~ 50 parts of sweet clover, Zhu Siberian cockleburs
25 parts ~ 50 parts of grass, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions, 20 parts ~ 40 parts of milkywhite pearleverlasting herb, 30 parts ~ 40 parts of wild rice stem, calabash
It is 25 parts ~ 35 parts of reed bar, 20 parts ~ 30 parts of beautiful hieracioides, 20 parts ~ 30 parts of dominant pulicaria flower, 20 parts ~ 25 parts of Rubus amphidasys Focke ex Diels, sweet
15 parts ~ 20 parts of grass, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts ~ 55 parts of caulis lonicerae, 20 parts ~ 30 parts of field pennycress, 20 parts ~ 30 parts of Snakegourd Fruit, Huang
Ten ~ 20 10 parts ~ 20 parts of a kind of reed mentioned in ancient books, 10 parts ~ 20 parts of dessert almond, 10 parts ~ 20 parts of lepidium seed, 5 parts ~ 15 parts of dried orange peel, jujube compositions.
2. mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer as described in claim 1, it is characterised in that medicine
Each component by weight by:20 parts of ganoderma lucidum, 20 parts of ginseng, 30 parts of sessile skullcap herb, 40 parts of sweet clover, 25 parts of Herba Gentianae tsinglingensis, an aromatic plant metioned in ancient books skin 30
Part, 30 parts of For-carrying green onions, 20 parts of milkywhite pearleverlasting herb, 30 parts of wild rice stem, 25 parts of faenum graecum, 20 parts of beautiful hieracioides, 20 parts of dominant pulicaria flower, peritricha hang
20 parts of hook, 15 parts of radix glycyrrhizae, raw 45 parts of the Radix Astragali, 45 parts of caulis lonicerae, 20 parts of field pennycress, 20 parts of Snakegourd Fruit, 10 parts of radix scutellariae, dessert almond 10
Ten part, 10 parts of lepidium seed, 5 parts of dried orange peel, jujube compositions.
3. mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer as described in claim 1, it is characterised in that treatment
Medicine each component by weight by:50 parts of ganoderma lucidum, 50 parts of ginseng, 60 parts of sessile skullcap herb, 50 parts of sweet clover, 50 parts of Herba Gentianae tsinglingensis, an aromatic plant metioned in ancient books
40 parts of skin, 40 parts of For-carrying green onions, 40 parts of milkywhite pearleverlasting herb, 40 parts, 35 parts of faenum graecum, 30 parts of beautiful hieracioides, 30 parts of dominant pulicaria flower,
25 parts of Rubus amphidasys Focke ex Diels, 20 parts of radix glycyrrhizae, raw 55 parts of the Radix Astragali, 55 parts of caulis lonicerae, 30 parts of field pennycress, 30 parts of Snakegourd Fruit, 20 parts of radix scutellariae,
20 20 parts of dessert almond, 20 parts of lepidium seed, 15 parts of dried orange peel, jujube compositions.
4. mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer as described in claim 1, it is characterised in that described
Medicine each component by weight by:30 parts of ganoderma lucidum, 30 parts of ginseng, 40 parts of sessile skullcap herb, 45 parts of sweet clover, 40 parts of Herba Gentianae tsinglingensis, an aromatic plant metioned in ancient books
35 parts of skin, 35 parts of For-carrying green onions, 30 parts of milkywhite pearleverlasting herb, 35 parts of wild rice stem, 30 parts of faenum graecum, 25 parts of beautiful hieracioides, 25 parts of dominant pulicaria flower, week
22 parts of raspberry of hair, 18 parts of radix glycyrrhizae, raw 50 parts of the Radix Astragali, 50 parts of caulis lonicerae, 25 parts of field pennycress, 25 parts of Snakegourd Fruit, 15 parts of radix scutellariae, sweet tea apricot
15 15 parts of benevolence, 15 parts of lepidium seed, 10 parts of dried orange peel, jujube compositions.
5. mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, its feature as described in claim 1 ~ 4 any one
It is, the medicine is tablet, dispersible tablet, decoction or capsule.
6. mitigate targeted therapy side reaction, the medicine of auxiliary treatment lung cancer, its feature as described in claim 1 ~ 4 any one
It is, the preparation method of medicine comprises the following steps:
20 parts ~ 50 parts of ganoderma lucidum, 20 parts ~ 50 parts of ginseng, 30 parts ~ 60 parts of sessile skullcap herb, sweet clover 40 parts ~ 50 are weighed by weight
Part, 25 parts ~ 50 parts of Herba Gentianae tsinglingensis, 30 parts ~ 40 parts of an aromatic plant metioned in ancient books skin, 30 parts ~ 40 parts of For-carrying green onions, 20 parts ~ 40 parts of milkywhite pearleverlasting herb, 30 parts of wild rice stem ~
40 parts, 25 parts ~ 35 parts of faenum graecum, 20 parts ~ 30 parts of beautiful hieracioides, 20 parts ~ 30 parts of dominant pulicaria flower, 20 parts of Rubus amphidasys Focke ex Diels ~
25 parts, 15 parts ~ 20 parts of radix glycyrrhizae, raw 45 parts ~ 55 parts of the Radix Astragali, 45 parts ~ 55 parts of caulis lonicerae, 20 parts ~ 30 parts of field pennycress, 20 parts of Snakegourd Fruit
~ 30 parts, 10 parts ~ 20 parts of radix scutellariae, 10 parts ~ 20 parts of dessert almond, 10 parts ~ 20 parts of lepidium seed, 5 parts ~ 15 parts of dried orange peel, and select high-quality
Ten ~ 20, jujube, it is standby;
To weigh each component cleaning, impurity elimination, 30 degrees Celsius ~ 40 degrees Celsius drying or naturally dry after be added to
In 1000 parts of water, it is heated to reflux 3 hours ~ 4 hours, filters, obtain filter residue and filtrate, the filtrate produces mitigation targeting
Treat side reaction, the medicine of auxiliary treatment lung cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711270783.5A CN107875311A (en) | 2017-12-05 | 2017-12-05 | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711270783.5A CN107875311A (en) | 2017-12-05 | 2017-12-05 | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107875311A true CN107875311A (en) | 2018-04-06 |
Family
ID=61772831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711270783.5A Pending CN107875311A (en) | 2017-12-05 | 2017-12-05 | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107875311A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110623964A (en) * | 2019-08-12 | 2019-12-31 | 浙江中医药大学 | Preparation method of ergosterol and gefitinib combined compound liposome freeze-dried powder, liposome and application |
CN110882257A (en) * | 2019-08-12 | 2020-03-17 | 浙江中医药大学 | Application of ergosterol and gefitinib combined |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406669A (en) * | 2011-11-11 | 2012-04-11 | 吉林天强制药有限公司 | Chinese medicine composite and preparation method and medicinal preparation thereof |
CN104306807A (en) * | 2014-11-18 | 2015-01-28 | 广东省中医院 | Compound preparation for treating advanced lung cancer and preparing method thereof |
CN104784561A (en) * | 2015-05-10 | 2015-07-22 | 顾克斌 | Medicine for treating lung cancer |
CN104807905A (en) * | 2015-05-04 | 2015-07-29 | 中国人民解放军第三七一医院 | Method for determining contents of ginsenosides Rg1 and Re in Xinnaoning tablet |
CN105832859A (en) * | 2016-04-21 | 2016-08-10 | 杨春莉 | Medicine for treating lung cancer |
-
2017
- 2017-12-05 CN CN201711270783.5A patent/CN107875311A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406669A (en) * | 2011-11-11 | 2012-04-11 | 吉林天强制药有限公司 | Chinese medicine composite and preparation method and medicinal preparation thereof |
CN104306807A (en) * | 2014-11-18 | 2015-01-28 | 广东省中医院 | Compound preparation for treating advanced lung cancer and preparing method thereof |
CN104807905A (en) * | 2015-05-04 | 2015-07-29 | 中国人民解放军第三七一医院 | Method for determining contents of ginsenosides Rg1 and Re in Xinnaoning tablet |
CN104784561A (en) * | 2015-05-10 | 2015-07-22 | 顾克斌 | Medicine for treating lung cancer |
CN105832859A (en) * | 2016-04-21 | 2016-08-10 | 杨春莉 | Medicine for treating lung cancer |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110623964A (en) * | 2019-08-12 | 2019-12-31 | 浙江中医药大学 | Preparation method of ergosterol and gefitinib combined compound liposome freeze-dried powder, liposome and application |
CN110882257A (en) * | 2019-08-12 | 2020-03-17 | 浙江中医药大学 | Application of ergosterol and gefitinib combined |
CN110882257B (en) * | 2019-08-12 | 2022-08-12 | 浙江中医药大学 | Application of ergosterol and gefitinib combined |
CN110623964B (en) * | 2019-08-12 | 2023-09-29 | 浙江中医药大学 | Preparation method of ergosterol and gefitinib combined compound liposome freeze-dried powder, liposome and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104547525A (en) | Drug composition for NSCLC (Non Small Cell Lung Cancer) prevention and preparation method thereof | |
CN103933425A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method thereof | |
CN102580000B (en) | Medicament for curing cancer pain and preparation method thereof | |
CN105596994A (en) | Medicine for treating lung cancer cell proliferation | |
CN107875311A (en) | A kind of mitigation targeted therapy side reaction, the medicine of auxiliary treatment lung cancer | |
CN101607011B (en) | Traditional Chinese medicine for treating cholecystitis post-operative complacation | |
CN105412818A (en) | Medicine for treating tumors and preparation method thereof | |
CN103263587B (en) | Traditional Chinese medicine preparation for treating toxic and side effects of nasopharyngeal carcinoma after radiotherapy and preparation method thereof | |
CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
CN105832859A (en) | Medicine for treating lung cancer | |
CN102614474A (en) | Traditional Chinese medicine for treating coronary heart disease and preparation method thereof | |
CN105663728A (en) | Traditional Chinese medicine compound preparation for treating colorectal cancer and preparation method thereof | |
CN110368440A (en) | Alleviate the Chinese medicine composition and preparation method thereof of side effect of digestive tract | |
CN104667012A (en) | Medicine for treating phlegm clouding clear orifices obstructive emphysema and preparation method of medicine | |
CN114869987B (en) | Traditional Chinese medicine composition for preventing liver cancer | |
CN102552619B (en) | Medicine for treating tumor and preparation method thereof | |
CN107095993A (en) | A kind of Chinese medicine for treating Respiratory Medicine bronchopulmonary aspergillosis | |
CN102631449A (en) | Chinese medicinal composition for treating acute pancreatitis | |
CN105597004A (en) | Traditional Chinese medicine combination for treating cancer | |
CN104491264A (en) | Heat and toxic material clearing preparation for treating esophageal cancer and preparation method of heat and toxic material clearing preparation | |
CN104984240A (en) | Medicine for treating schizotypal personality disorder | |
CN103860991B (en) | Acute heart failure invigorating QI and tranquilization electuary and preparation method | |
CN104623385A (en) | Pharmaceutical compound for treating mammary gland hyperplasia and preparation method of pharmaceutical compound | |
CN104383478A (en) | Traditional Chinese medicine for treating stomach cancer | |
CN102416059B (en) | Medicinal composition for treating colon cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180406 |